|Articles|August 10, 2022
How Medable eConsent Expands Patient Access, Reduces Costs
Author(s)Medable
Medable eConsent improves the trial experience for patients, sites, & sponsors. Learn how eConsent in conjunction with other decentralized solutions helped save one organization save $20M in trial costs, reduce trial site visits by 75%, and cut enrollment timelines in half with this case study.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
How Biopharma Navigates the 2026 Economic Shift
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5